Nov 25, 2024 8:35 am EST TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
Oct 23, 2024 8:30 am EDT TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Oct 22, 2024 9:00 am EDT TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event